Vioxx Trial Notes for 9/26/05, from various sources including Yahoo, Reuters, those there in the audience ...
On the stand all morning (day 3 of his testimony) is David Anstice. He is the head of human health division. Anstice said that Merck was worried about the impact on Vioxx's sales if the cardiovascular data was included in the "Warning" section of its label.
Humeston's attorney showed him a document that addressed the CVE mention in the "Warnings" section could have cut Vioxx's sales by up to 50% per year.
Counsel also showed the jury several documents that showed that several members of an "independent panel" advising Merck on Vioxx's label had previously received been paid by Merck for work.
Week three continues.